1-3 of 3
Mark Raffeld
Close
Sort by
Journal Articles

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

Clinical Trials & Observations
Dai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, Constance Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, Julie Feurtado, Lacey James-Echenique, Chin-Hsien Tai, Keyur P. Patel, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Alina Dulau-Florea, Robert J. Kreitman
Journal: Blood Advances
Blood Adv (2021) 5 (23): 4807–4816.
https://doi.org/10.1182/bloodadvances.2021005039
Published: 2021
Journal Articles

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Clinical Trials & Observations
Nirali N. Shah, Haiying Qin, Bonnie Yates, Ling Su, Haneen Shalabi, Mark Raffeld, Mark A. Ahlman, Maryalice Stetler-Stevenson, Constance Yuan, Shuang Guo, Siyuan Liu, Stephen H. Hughes, Terry J. Fry, Xiaolin Wu
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2317–2322.
https://doi.org/10.1182/bloodadvances.2019000219
Published: 2019
Journal Articles

The clinical spectrum of Erdheim-Chester disease: an observational cohort study

Clinical Trials & Observations
Juvianee I. Estrada-Veras, Kevin J. O’Brien, Louisa C. Boyd, Rahul H. Dave, Benjamin H. Durham, Liqiang Xi, Ashkan A. Malayeri, Marcus Y. Chen, Pamela J. Gardner, Jhonell R. Alvarado Enriquez, Nikeith Shah, Omar Abdel-Wahab, Bernadette R. Gochuico, Mark Raffeld, Elaine S. Jaffe, William A. Gahl
Journal: Blood Advances
Blood Adv (2017) 1 (6): 357–366.
https://doi.org/10.1182/bloodadvances.2016001784
Published: 2017
Includes: Supplemental data